Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Phase II trial of irofulven for treatment of glioma commences

May 8, 2001

Pharmacyclics reacquires worldwide rights to Lutrin

May 8, 2001

New kinase inhibitors under study at Pfizer

May 7, 2001

Research at BASF leads to identification of inhibitors of angiogenic kinases

May 4, 2001

Baylor U. designs new cytotoxic tubulin polymerization inhibitors

May 4, 2001

Phase II trial evaluates combination of peptide and standard chemotherapy for ovarian cancer

May 4, 2001

In vivo antitumor and apoptosis-inducing activity described for new proteasome inhibitor

May 4, 2001

Dibenzophenanthroline G-quadruplex ligands inhibit telomerase activity

May 4, 2001

MitoExtra and mitomycin C bioequivalent in phase I study

May 4, 2001

Paclitaxel-chlorambucil hybrid shows supraadditive activity in certain tumor models

May 4, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...